These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 31570586)

  • 1. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
    Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
    Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
    Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1.
    Nguyen L; Luu LM; Peng S; Serrano JF; Chan HY; Zimmerman SC
    J Am Chem Soc; 2015 Nov; 137(44):14180-9. PubMed ID: 26473464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
    Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
    Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
    González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
    PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
    Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
    ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
    Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
    Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
    Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
    Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features.
    Dansithong W; Wolf CM; Sarkar P; Paul S; Chiang A; Holt I; Morris GE; Branco D; Sherwood MC; Comai L; Berul CI; Reddy S
    PLoS One; 2008; 3(12):e3968. PubMed ID: 19092997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
    Michel L; Huguet-Lachon A; Gourdon G
    PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
    Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
    Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
    Angelbello AJ; Rzuczek SG; Mckee KK; Chen JL; Olafson H; Cameron MD; Moss WN; Wang ET; Disney MD
    Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7799-7804. PubMed ID: 30926669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1.
    Wheeler TM; Krym MC; Thornton CA
    Neuromuscul Disord; 2007 Mar; 17(3):242-7. PubMed ID: 17306536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
    André LM; van Cruchten RTP; Willemse M; Wansink DG
    PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila.
    Houseley JM; Wang Z; Brock GJ; Soloway J; Artero R; Perez-Alonso M; O'Dell KM; Monckton DG
    Hum Mol Genet; 2005 Mar; 14(6):873-83. PubMed ID: 15703191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
    Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
    Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
    Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
    Chau A; Kalsotra A
    Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients.
    Botta A; Rinaldi F; Catalli C; Vergani L; Bonifazi E; Romeo V; Loro E; Viola A; Angelini C; Novelli G
    J Med Genet; 2008 Oct; 45(10):639-46. PubMed ID: 18611984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.